Skip to main content
We may receive compensation from affiliate partners for some links on this site. Read our full Disclosure here.

Sweden Pauses Moderna COVID-19 Jab for Under 30 Due to Risk of Myocarditis


Sweden remained out of the news for a while.

As time proved the Scandinavian nation right not to enforce strict lockdowns, the mainstream media refused to touch the subject.

But Sweden has made headlines once again.

Did Sweden fold under pressure to the mainstream narrative for the experimental COVID-19 jabs?

Well, not exactly.

Sweden made another common sense decision that other countries should follow.

Read below for more:

While I’d prefer the entire program to shut down, this is a giant step in the right direction.

The link between the experimental COVID-19 jabs and myocarditis is established in countries such as the United States, Canada, and Israel.

Data shows COVID-19 induced myocarditis primarily impacts younger populations.

The risk-benefit ratio is all risk and zero benefit.

Sweden took a step in the right direction, but I highly doubt the United States follows.

The CDC is too focused on providing boosters to frontline workers, regardless of age.

Once again, it’s Sweden who plays the black sheep and ignores the mainstream COVID-19 narrative.

Translated from Folkhälsomyndigheten:

The Swedish Public Health Agency has decided to pause the use of Moderna’s vaccine Spikevax, for everyone born in 1991 and later, for precautionary reasons. The cause is signals of an increased risk of side effects such as inflammation of the heart muscle or heart sac. However, the risk of being affected is very small.

Myocarditis (pericarditis) and pericarditis usually go away on their own, but the symptoms need to be assessed by a doctor. The conditions are most common among young men, in connection with, for example, viral infections such as covid-19. In 2019, approximately 300 people under the age of 30 were treated in hospital with myocarditis.

Data point to an increased incidence also in connection with vaccination against covid-19 , mainly in adolescents and young adults and mainly in boys and men. For the individual, the risk of being affected is very small, it is a very rare side effect.

New preliminary analyzes from Swedish and Nordic data sources indicate that the connection is especially clear when it comes to Moderna’s vaccine Spikevax, especially after the second dose. The increase in risk is seen within four weeks after the vaccination, mainly within the first two weeks.

The Swedish Public Health Agency has decided to recommend a break for all use of Spikevax for people born in 1991 and later. The Comirnaty vaccine from Pfizer / Biontech is recommended for these age groups instead. The decision is valid until 1 December 2021. The Swedish Public Health Agency will return with a notice of recommendation after this date.

– We follow the situation closely and act quickly to ensure that vaccinations against covid-19 are always as safe as possible and at the same time provide effective protection against covid-19, says Anders Tegnell, head of department and state epidemiologist at the Swedish Public Health Agency.

People born in 1991 and later who have received a dose of Moderna’s vaccine will not be offered a second dose of covid-19 vaccine at present, discussions are ongoing about the best solution for that group. In total, there are about 81,000 people.

– Those who have been vaccinated recently, with their first or second dose of Moderna’s vaccine, do not have to worry about the risk is very small, but it is good to know what symptoms you need to be vigilant about, says Anders Tegnell.

Both myocarditis and pericarditis often go away on their own, without causing any lasting problems, but suspicious symptoms should be assessed by a doctor at, for example, a health center or emergency room. Medical treatment and monitoring in hospital may be needed in established cases.


Join the conversation!

Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!

Hey, Noah here!

Wondering where we went?

Read this and bookmark our new site!

See you over there!

Thanks for sharing!